Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Amneal Wins European Commission Marketing Authorization for Adcomfo

Amneal Wins European Commission Marketing Authorization for Adcomfo

MT newswireMT newswire2026/11/17 20:35
04:35 PM EST, 11/17/2026 (MT Newswires) -- Amneal Pharmaceuticals (AMRX) said late Tuesday the European Commission has granted marketing authorization for Adcomfo, a biosimilar to Novartis' (NVS) Xolair. Adcomfo, also known as ADL-018/AVT23, was developed by Kashiv BioSciences in partnership with Alvotech. Amneal acquired Kashiv in August, the company said. Adcomfo is approved for the treatment of severe persistent allergic asthma, severe chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, the company said. It is approved in 75 mg, 150 mg and 300 mg presentations in pre-filled syringe and 75 mg and 150 mg pre-filled pen configurations. In the US, Amneal's biologics license application for its proposed biosimilar to Xolair is under review by the US Food and Drug Administration.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

South Korean think tanks significantly raise 2027 economic growth forecasts, betting on continued AI chip boom

The Korea Development Institute (KDI) raised its economic growth forecast for this year and next on Wednesday, betting that the global artificial intelligence (AI) boom will continue to drive semiconductor exports and investment, helping the South Korean economy maintain its growth momentum.

智通财经•2026/11/18 04:12

SQM.US Q3 profit misses expectations; lithium price declines but demand outlook remains “encouraging”

SQM.US still reports seeing "encouraging" potential demand trends.

智通财经•2026/11/18 03:16

Mizuho: Consecutive system outages in the US trigger stockpiling surge! With short-term demand boosted, Costco (COST.US) sales momentum is expected to remain strong.

According to a report by Mizuho Securities analysts, following a series of recent system failures in the United States, consumers have started stockpiling essential goods, leading to a short-term surge in demand for Costco, a members-only retailer.

智通财经•2026/11/18 03:07
Mizuho: Consecutive system outages in the US trigger stockpiling surge! With short-term demand boosted, Costco (COST.US) sales momentum is expected to remain strong.

Biogen (BIIB.US) announces mid-stage trial data for early Alzheimer's candidate drug diranersen: significant slowing of clinical decline over two years

Biogen has released the latest interim clinical trial data for its early-stage Alzheimer's disease candidate drug, diranersen.

智通财经•2026/11/18 03:02
Biogen (BIIB.US) announces mid-stage trial data for early Alzheimer's candidate drug diranersen: significant slowing of clinical decline over two years